The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer

Alisha Bent, Shreya Raghavan, Arvind Dasari, Scott Kopetz

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Our understanding of the diagnostic and prognostic use of circulating tumor DNA (ctDNA) in colorectal cancer (CRC) has broadly expanded over the past few years. The utilization of ctDNA to detect minimal residual disease is currently being employed across the continuum of cancer care. The lead-time of ctDNA positivity to radiographic recurrence in stage I to III CRC is up to 9 months on average, which provides a therapeutic window for a group of high-risk patients who will ultimately recur. There are several ongoing prospective clinical trials that investigate whether ctDNA can be used as an integral biomarker to risk stratify CRC patients and guide adjuvant treatment decisions. In this review, we summarize the evidence supporting the promise of ctDNA-defined MRD in CRC and highlight the current ctDNA guided adjuvant prospective clinical trials.

Original languageEnglish (US)
Pages (from-to)89-95
Number of pages7
JournalClinical colorectal cancer
Volume21
Issue number2
DOIs
StatePublished - Jun 2022

Keywords

  • Biomarkers
  • Circulating tumor DNA
  • Clinical trials
  • Colon cancer
  • Liquid biopsy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer'. Together they form a unique fingerprint.

Cite this